Skip to main content
SpringerLink
Log in

Cytokine/chemokine dysregulation in progressive MS patient is apparent and can be modulated by calpain inhibition

  • Original Article
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract

This study examines the cytokine/chemokine profile of a 62-year-old African American male with progressive multiple sclerosis (MS). MRI images of the MS patient demonstrated generalized white matter involvement with multiple lesions in the periventricular area. A 42-plex Discovery Assay® (Eve Technologies) of the patient’s plasma and peripheral blood mononuclear cells (PBMCs) supernatant or PBMC-derived T cell supernatant samples from two separate clinic visits revealed vastly differing cytokine/chemokine levels. In addition, certain cytokine/chemokine profiles had notable differences when compared to the larger patient group or patients’ PBMCs treated with a calpain inhibitor in vitro. Interestingly, large numbers of cytokines/chemokines and growth factors in MS PBMCs are modulated by calpain inhibition, suggesting the clinical significance of these findings in designing better therapeutics against progressive MS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Aktas O, Kieseier B, Hartung HP (2010) Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci 33:140–152

    Article  CAS  Google Scholar 

  • Alroughani R, Deleu D, El Salem K, Al-Hashel J, Alexander KJ, Abdelrazek MA, Aljishi A, Alkhaboori J, Al Azri F, Al Zadjali N, Hbahbih M, Sokrab TE, Said M, Rovira A (2016) A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. BMC Neurol 16:240

    Article  Google Scholar 

  • Banik NL, Chakrabarti AK, Hogan EL (1987) Distribution of calcium activated neutral proteinase (mM CANP) in myelin and cytosolic fractions in bovine brain white matter. Life Sci 41:1089–1095

    Article  CAS  Google Scholar 

  • Cardenas-Roldan J, Rojas-Villarraga A, Anaya JM (2013) How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Med 11:73

    Article  CAS  Google Scholar 

  • Casella G, Garzetti L, Gatta AT, Finardi A, Maiorino C, Ruffini F, Martino G, Muzio L, Furlan R (2016) IL4 induces IL6-producing M2 macrophages associated to inhibition of neuroinflammation in vitro and in vivo. J Neuroinflammation 13:139

    Article  Google Scholar 

  • Chandran R, Capone M, Matzelle D, Polcyn R, Kau E, Haque A, Banik NL (2018) Distinct cytokine and chemokine expression in plasma and Calpeptin-treated PBMCs of a relapsing-remitting multiple sclerosis patient: A case report. Neurochem Res 43:2224–2231

    Article  CAS  Google Scholar 

  • De Stefano N, Giorgio A, Battaglini M, Rovaris M, Sormani MP, Barkhof F, Korteweg T, Enzinger C, Fazekas F, Calabrese M, Dinacci D, Tedeschi G, Gass A, Montalban X, Rovira A, Thompson A, Comi G, Miller DH, Filippi M (2010) Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 74:1868–1876

    Article  Google Scholar 

  • Filipovic R, Jakovcevski I, Zecevic N (2003) GRO-alpha and CXCR2 in the human fetal brain and multiple sclerosis lesions. Dev Neurosci 25:279–290

    Article  CAS  Google Scholar 

  • Guyton MK, Brahmachari S, Das A, Samantaray S, Inoue J, Azuma M, Ray SK, Banik NL (2009) Inhibition of calpain attenuates encephalitogenicity of MBP-specific T cells. J Neurochem 110:1895–1907

    Article  CAS  Google Scholar 

  • Guyton, M. K., Das, A., Matzelle, D. D., Samantaray, S., Azuma, M., Inoue, J., Ray, S. & Banik, N. L. 2006. SJA6017 attenuates immune cell infiltration and Neurodegneration in EAE. 8th International Congress of Neuroimmunology, 107-112

  • Guyton MK, Das A, Samantaray S, Wallace GCT, Butler JT, Ray SK, Banik NL (2010) Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis. J Neurosci Res 88:2398–2408

    CAS  PubMed  PubMed Central  Google Scholar 

  • Guyton MK, Wingrave JM, Yallapragada AV, Wilford GG, Sribnick EA, Matzelle DD, TYOR WR, Ray SK, Banik NL (2005) Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto-immune encephalomyelitis. J Neurosci Res 81:53–61

    Article  CAS  Google Scholar 

  • Imam SA, Guyton MK, Haque A, Vandenbark A, Tyor WR, Ray SK, Banik NL (2007) Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol 190:139–145

    Article  CAS  Google Scholar 

  • Kalinski P, Vieira PL, Schuitemaker JH, De Jong EC, Kapsenberg ML (2001) Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 97:3466–3469

    Article  CAS  Google Scholar 

  • Kalman B, Leist TP (2004) Familial multiple sclerosis and other inherited disorders of the white matter. Neurologist 10:201–215

    Article  Google Scholar 

  • Kawada K, Upadhyay G, Ferandon S, Janarthanan S, Hall M, Vilardaga JP, Yajnik V (2009) Cell migration is regulated by platelet-derived growth factor receptor endocytosis. Mol Cell Biol 29:4508–4518

    Article  CAS  Google Scholar 

  • Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911

    Article  CAS  Google Scholar 

  • Lublin f D, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell b, Barkhof F, jr. Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O’connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stuve O, Waubant E, Polman CH (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:278–286

    Article  Google Scholar 

  • Masuda H, Mori M, Uchida T, Uzawa A, Ohtani R, Kuwabara S (2017) Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. J Neuroimmunol 305:102–107

    Article  CAS  Google Scholar 

  • Mori F, Rossi S, Piccinin S, Motta C, Mango D, Kusayanagi H, Bergami A, Studer V, Nicoletti CG, Buttari F, Barbieri F, Mercuri NB, Martino G, Furlan R, Nistico R, Centonze D (2013) Synaptic plasticity and PDGF signaling defects underlie clinical progression in multiple sclerosis. J Neurosci 33:19112–19119

    Article  CAS  Google Scholar 

  • Payne NL, Dantanarayana A, Sun G, Moussa L, Caine S, Mcdonald C, Herszfeld D, Bernard CC, Siatskas C (2012) Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination. Cell Adhes Migr 6:179–189

    Article  Google Scholar 

  • Rossi C, Cusimano M, Zambito M, Finardi A, Capotondo A, Garcia-Manteiga JM, Comi G, Furlan R, Martino G, Muzio L (2018) Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis. Cell Death Dis 9:250

    Article  Google Scholar 

  • Schaecher KE, Shields DC, Banik NL (2001) Mechanism of myelin breakdown in experimental demyelination: a putative role for calpain. Neurochem Res 26:731–737

    Article  CAS  Google Scholar 

  • Shields DC, Banik NL (1998) Putative role of calpain in the pathophysiology of experimental optic neuritis. Exp Eye Res 67:403–410

    Article  CAS  Google Scholar 

  • Shields DC, Schaecher KE, Saido TC, Banik NL (1999) A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci U S A 96:11486–11491

    Article  CAS  Google Scholar 

  • Shields DC, Tyor WR, Deibler GE, Hogan EL, Banik NL (1998) Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 95:5768–5772

    Article  CAS  Google Scholar 

  • Smith AW, Das A, Guyton MK, Ray SK, Rohrer B, Banik NL (2011a) Calpain inhibition attenuates apoptosis of retinal ganglion cells in acute optic neuritis. Invest Ophthalmol Vis Sci 52:4935–4941

    Article  CAS  Google Scholar 

  • Smith AW, Doonan BP, Tyor WR, Abou-Fayssal N, Haque A, Banik NL (2011b) Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients. J Neuroimmunol 232:179–185

    Article  CAS  Google Scholar 

  • Trager N, Butler JT, Haque A, Ray SK, Beeson C, Banik NL (2013) The involvement of Calpain in CD4(+) T helper cell Bias in Multple sclerosis. J Clin Cell Immunol 4:1000153

    Article  Google Scholar 

  • Trager N, Smith A, Wallace IV G, Azuma M, Inoue J, Beeson C, Haque A, Banik NL (2014) Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis. J Neurochem 130:268–279

    Article  CAS  Google Scholar 

  • Tullman MJ (2013) Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care 19:S15–S20

    PubMed  Google Scholar 

Download references

Acknowledgements

This study was made possible by grants from the Ralph H. Johnson Veterans Administration Medical Center, Charleston (1I01BX002349-01, 1 I01 BX004269-01A1) to NLB. This work was also supported by grants from the South Carolina Spinal Cord Injury Research Fund (SCIRF #2018 I-01) to AH.

Author information

Authors and Affiliations

  1. Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA

    Rachel Polcyn, Mollie Capone, Azizul Haque & Naren Banik

  2. Department of Neurosurgery, Medical University of South Carolina, 96 Jonathan Lucas St, MSC606, Charleston, SC, 29425, USA

    Mollie Capone, Denise Matzelle & Naren Banik

  3. Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA

    Denise Matzelle, Aljoeson Walker, Elizabeth Kau & Naren Banik

  4. Department of Neurology, Medical University of South Carolina, Charleston, SC, USA

    Brittany Lueking & Aljoeson Walker

  5. Department of ophthalmology, Medical University of South Carolina, Charleston, SC, USA

    Aljoeson Walker

Authors
  1. Rachel Polcyn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mollie Capone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Denise Matzelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brittany Lueking
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aljoeson Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elizabeth Kau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Azizul Haque
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Naren Banik
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Rachel Polcyn wrote the manuscript and drew the figures. Mollie Capone performed the experiments. Denise Matzelle coordinated the patient study, collected samples, and edited the manuscript. Aljoeson Walker and Brittany Lueking evaluated the patient and provided us with the MRI images. Elizabeth Kau evaluated the patient and provided us with the patient blood samples. Azizul Haque conceived and designed the experiments and the manuscript. Naren Banik also conceived and designed the manuscript. Azizul Haque and Naren Banik also edited the manuscript. All authors reviewed and approved the final version of the manuscript.

Corresponding authors

Correspondence to Azizul Haque or Naren Banik.

Ethics declarations

Conflict of interest

The authors have no financial conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Polcyn, R., Capone, M., Matzelle, D. et al. Cytokine/chemokine dysregulation in progressive MS patient is apparent and can be modulated by calpain inhibition. Metab Brain Dis 35, 255–261 (2020). https://doi.org/10.1007/s11011-019-00521-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11011-019-00521-1

Keywords

Search

Navigation